STOCK TITAN

Passage Bio, Inc. - PASG STOCK NEWS

Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.

Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.

Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.

Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.

Rhea-AI Summary

Passage Bio (Nasdaq: PASG) reported Q2 2024 financial results and business highlights. Key points include:

  • Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial
  • FDA agreed to expand upliFT-D trial to include FTD-C9orf72 patients
  • Out-licensed pediatric lysosomal storage disease programs to GEMMA Biotherapeutics
  • Cash runway extended to end of Q2 2026
  • Q2 2024 financials: $91.8M cash position, $10.4M R&D expenses, $6.5M G&A expenses, $16.0M net loss ($0.26 per share)

The company plans to present updated safety and biomarker data from Cohort 1 FTD-GRN patients at ISFTD2024 in September 2024 and expects to initiate dosing of FTD-C9orf72 patients in 1H 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
-
Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, has announced its participation in two upcoming investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, in Boston, MA, where management will give a presentation at 8:00 a.m. ET and participate in investor meetings. Additionally, Passage Bio will attend the 15th Annual Wedbush PacGrow Healthcare Conference on August 14, 2024, in New York City, NY, participating in investor meetings.

A live webcast of the Canaccord Genuity conference presentation will be available on the Investors & Media section of Passage Bio's website, with a replay accessible for 30 days following the event. This participation in investor conferences demonstrates Passage Bio's commitment to engaging with the investment community and sharing updates on their progress in developing treatments for neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
-
Rhea-AI Summary

Passage Bio (NASDAQ: PASG) has out-licensed three pediatric gene therapy programs to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson. The deal includes exclusive, worldwide rights for PBGM01 (GM1 gangliosidosis), PBKR03 (Krabbe disease), and PBML04 (metachromatic leukodystrophy). Passage Bio will receive initial payments of $10 million, with potential for up to $124 million in additional milestones and future royalties.

The company also entered a new strategic research collaboration with GEMMA Biotherapeutics, focusing on CNS indications including Huntington's disease. This transaction is expected to extend Passage Bio's operating cash runway to the end of Q2 2026, allowing the company to focus on advancing its lead asset, PBFT02, in multiple adult neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
Rhea-AI Summary

Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. This expansion is supported by compelling preclinical evidence and safety data from the first cohort of FTD-GRN patients treated with PBFT02.

FTD-C9orf72 affects approximately 21,000 individuals in the US and Europe. The FDA has granted PBFT02 Fast Track and Orphan Drug designations, while the European Commission has also given it Orphan designation. This development could bring new hope to an underserved patient community with clinical trial options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
-
Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO William Chou, M.D., will deliver the presentation on June 12, 2024, at 4:00 p.m. ET. The live webcast and a 30-day replay will be accessible on Passage Bio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
-
Rhea-AI Summary

Passage Bio (Nasdaq: PASG), a clinical stage genetic medicines company, announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship. This award honors Dr. Tachi Yamada, the co-founder and former Chairman, and supports life sciences students in Pennsylvania. Carrie, pursuing a degree in Biological Science with a minor in Neuroscience, has a passion for neurology and aims to provide healthcare to underserved communities. The scholarship provides financial assistance and a mentor from Passage Bio for professional growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
Rhea-AI Summary

Passage Bio (NASDAQ: PASG) reported its Q1 2024 financial results and provided business updates, including advances in its global upliFT-D clinical trial for FTD-GRN. The trial's Dose 1 PBFT02 consistently elevated CSF progranulin at six months in two patients. All five patients in Cohort 1 have been dosed, with safety and biomarker data expected in 2H 2024. Cohort 2 dosing is planned to start by the end of 1H 2024. The company initiated discussions with the FDA for using PBFT02 to treat FTD-C9orf72, with feedback expected in 2H 2024. Financially, the company ended Q1 with $104.5 million in cash, projecting a cash runway into Q4 2025. Net loss decreased to $16.7 million from $34.3 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.47%
Tags
-
Rhea-AI Summary
Passage Bio, Inc. (NASDAQ: PASG) will present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event features William Chou, M.D., president, and CEO, and Eden Fucci, SVP of technical operations, in a virtual fireside chat on April 29, 2024. Investors can watch the webcast on Passage Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Summary
Passage Bio, Inc. (PASG) announces the opening of its third annual Tachi Yamada Scholarship program, offering a $10,000 scholarship to a junior life science major at a Pennsylvania-based four-year college. The scholarship is in honor of Tachi Yamada, a co-founder of Passage Bio, and aims to support students pursuing careers in the life sciences industry. Interested sophomore students have until April 26, 2024, to apply for the scholarship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
Rhea-AI Summary
Passage Bio, Inc. (PASG) reports positive financial results and progress in the upliFT-D trial of PBFT02 for frontotemporal dementia (FTD) treatment. The company expands clinical trial sites into Europe and activates seven global sites. PBFT02 shows potential in treating various neurodegenerative diseases, with a strong balance sheet until Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Passage Bio, Inc.

Nasdaq:PASG

PASG Rankings

PASG Stock Data

20.51M
54.96M
0.48%
60.63%
2.93%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA